Target intelligence / Profile preview

Selenium-binding protein 1 (SELENBP1)

Target
SELENBP1
Molecular classification
Enzyme (methanethiol oxidase), Other (selenium-binding protein family)
01

Overview

Selenium-binding protein 1 (SELENBP1) is a highly conserved intracellular protein that covalently binds selenium and belongs to the selenium-binding protein family. It exhibits methanethiol oxidase activity, converting methanethiol—a gut bacteria-derived organosulfur compound—into products such as hydrogen peroxide and hydrogen sulfide, which participate in redox regulation and cell signaling. SELENBP1 is implicated in critical biological functions including redox balance, intracellular protein degradation, intra-Golgi protein transport, and cell differentiation and motility. It has gained attention for its tumor suppressor role, as downregulation in various cancers is associated with poor outcomes. Additionally, altered SELENBP1 levels serve as biomarkers for cancer prognosis, cardiac injury, and neurological trauma. Its exact physiological and pathological roles remain an active area of research, and there are no approved drugs directly targeting SELENBP1 as of 2024.

Other names
SBP1hSP56LPSBSBP56SP5656 kDa selenium-binding proteinLp56SELENBP1Selenbp2
02

Mechanism of action

Not applicable (no direct pharmacological inhibitors or activators established for SELENBP1 as of 2024)

03

Biological functions

Methanethiol oxidation (methanethiol oxidase activity)Protein degradation (ubiquitination/deubiquitination-mediated)Redox modulation and oxidative stress responseIntra-Golgi protein transportCellular differentiation (especially in epithelial and adipocyte cells)Cell motilityProtein transportSensing of reactive xenobiotics
04

Disease associations

Cancer (notably acts as a tumor suppressor; low expression associated with poor prognosis)Neurological disease (e.g., as biomarker in traumatic spinal cord injury)Cardiovascular disease (biomarker for myocardial infarction and hypoxic stress)Adipogenesis and metabolic diseasesOther (stress response in cells, marker of cell differentiation)
05

Safety considerations

None specific to therapeutic targeting, since no established drugs or direct modulators exist; potential challenges include understanding context-specific roles and cell-type specificity in safety profiling
06

Interacting drugs

None directly clinically established
07

Biomarkers

Circulating SELENBP1 protein levels (as marker for neurological recovery in spinal cord injury)Elevated SELENBP1 in serum (marker for myocardial infarction or cardiac stress)Reduced SELENBP1 in tumor tissue (marker of prognosis in several cancers including melanoma and prostate cancer)

Beyond the preview

Go deeper on Selenium-binding protein 1 (SELENBP1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Selenium-binding protein 1 (SELENBP1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call